Navigation Links
Selexis SA to Speak on Next Generation Innovations for Secretion Bottlenecks at the 2013 Protein Engineering Summit (PEGS)

Geneva, Switzerland (PRWEB) April 23, 2013

Geneva, Switzerland - April 23, 2013 – Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s vice present of business development, Andrew Sandford, will be speaking on The Selexis SURE CHO-Mplus™ Libraries: Next Generation Innovation for Addressing Difficult-to-Express Proteins at the 2013 PEGS Summit on Wednesday, May 1, 2013 at the Seaport World Trade Center in Boston, Massachusetts. Selexis will also be exhibiting at the conference, April 29 – May 3, 2013.

Andrew Sandford’s lecture is part of the Engineering Antibodies track. Conference attendees can hear Mr. Sandford’s lecture on Wednesday, May 1 at 3:05 PM.

Presentation Abstract:
Tackling production bottlenecks with difficult-to-express (DTE) proteins can significantly delay development programs. The SURE CHO-Mplus™ Libraries, the newest innovation from the SUREtechnology Platform™, consists of proprietary libraries specifically designed to address a range of production bottlenecks, including metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications. The libraries allow for parallel experimentation to overcome DTE protein development issues in a shorter timeframe.

Additionally, conference attendees can meet Selexis representatives at Booth 321, April 29 – May 3. To schedule meetings in advance, please contact Selexis at

Registration for the PEGS conference is required. For more information, visit

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selexis SA to Present at Biotech Showcase 2012
2. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
3. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
4. Selexis SA to Present at Cell Line Development and Engineering 2013
5. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
6. Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference
7. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
8. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
9. Bunker Hill Community College Student Speaks at 2012 BIO International Convention
10. Human Genome Decoder and Artificial Life Creator, J. Craig Venter to Speak at "The Atlantic Meets the Pacific"
11. VBI’s Dr. Szczepan Baran is an Invited Speaker at the Swiss Laboratory Animal (SGV) National Meeting
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):